Login to Your Account



Halozyme Sinks as FDA Asks for HyQ Long-Term-Use Data

By Trista Morrison
Staff Writer

Tuesday, April 17, 2012
Shares of Halozyme Therapeutics Inc. fell 24 percent Monday after the biotech and partner Baxter International Inc. revealed the FDA needs more information to complete its review of subcutaneous immunoglobulin product HyQ.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription